Aims of the study-To identify the proportion and type of deletions present in the glypican 3 (GPC3) gene in a group of patients with Simpson-Golabi-Behmel syndrome (SGBS). Subjects and methods-PCR analysis using primer pairs which amplify fragments from each of the eight exons of the GPC3 gene was carried out in a series of 18 families with SGBS (approximately half of reported cases). Results-Deletions were detected in only five families (one reported previously). We found deletions in all exons of the gene except exon 3.
using primer pairs which amplify fragments from each of the eight exons of the GPC3 gene was carried out in a series of 18 families with SGBS (approximately half of reported cases). Results-Deletions were detected in only five families (one reported previously). We found deletions in all exons of the gene except exon 3.
Conclusions-Our results suggest that large scale deletions may be less common in SGBS than was originally thought. One patient, with an exon 4 and 5 deletion, lacked the characteristic facial dysmorphic features. This raises the possibility of involvement of GPC3 gene defects in a wider range (SGBS-7) ). The same group have recently reported finding a further four independent deletions.9
We have identified five different deletions in SGBS-4, 5, 7, 25, and 27. Although the affected subjects in SGBS-7, 25, and 27 have similar phenotypes (table 1) they have very different deletions: in SGBS-7 the deletion is of exons 6 to 8, in SGBS-25 it is exon 1, while in SGBS-27 it is of exon 8. There are subtle differences in the phenotypes, however; for example, the affected subjects in SGBS-7 and 27 have renal tract abnormalities while in SGBS-25 the affected person does not. In addition to the features shown in table 1, SGBS-25 also had a submucous cleft palate which was repaired. The younger of the two affected males in SGBS-7 developed hydrocephalus and has required the insertion of a ventriculoperitoneal shunt. This complication has not previously been described in SGBS, although a male in SGBS-12 is similarly affected. The significance of these differences is unclear at present.
The affected male in SGBS-4 (deleted for exons 1 There is significant overlap in phenotype between SGBS and BWS.'0 Indeed, this and the fact that SGBS has only relatively recently been delineated as a single entity probably means that SGBS is underdiagnosed. The IGF2 gene (which maps to lIp 15.5) has been implicated in the underlying molecular pathology of BWS7 and there is now evidence to suggest that there is an interaction between GPC3 and IGF2.6 Evidence from mouse mutants also indicates that abnormalities of IGF2 expression affect growth.'1 12 It may, therefore, also be valuable to look for mutations in the GPC3 gene in male BWS patients, for whom there is no indication of chromosome 11 involvement.
